Analysis of safety and pharmacodynamics of SANA in human volunteers Based on all the accumulated preclinical evidence supporting that SANA might be a suitable first-in-class drug for treatment of obesity and comorbidities, we performed a randomized, double-blind, placebo-controlled phase 1A/B clinical trial in healthy lean volunteers and in volunteers with obesity
Pricing for FDA-approved brand-name GLP-1 medications is aligned with the lowest available cash price nationally through manufacturer savings programs when eligibility criteria are met
On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002
In the fourth quarter of 2024, GLP-1 sales accounted for 30% of Himss $481 million in total revenue, and it was estimated that Hims was responsible for 20% of all compounded GLP-1 prescriptions in the US during that period
It continues with meticulous handling and storage practices in the lab
Propolis exhibited a substantial reduction in the quantity of Lactobacillus delbrueckii subsp